Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;6:e2200197. doi: 10.1200/PO.22.00197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Association between therapeutic response and the 5-year outcome. Five-year probabilities of (A, C, and E) DMFS and (B, D, and F) OS stratified by pCR were assessed by the log-rank test for each BluePrint subtype: (A and B) cHER2/gLuminal, (C and D) cHER2/gHER2, and (E and F) cHER2/gBasal. cHER2, clinically defined HER2+; DMFS, distant metastasis-free survival; gBasal, genomically defined Basal-Type; gHER2, genomically defined HER2-Type; gLuminal, genomically defined Luminal-Type; HER2, human epidermal growth factor receptor 2; OS, overall survival; pCR, pathologic complete response.